454 related articles for article (PubMed ID: 20806117)
21. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
Hinder M; Frick A; Jordaan P; Hesse G; Gebauer A; Maas J; Paccaly A
Clin Pharmacol Ther; 2006 Dec; 80(6):691-702. PubMed ID: 17178269
[TBL] [Abstract][Full Text] [Related]
22. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels.
Tello-Montoliu A; Marín F; Roldán V; Mainar L; López MT; Sogorb F; Vicente V; Lip GY
J Intern Med; 2007 Dec; 262(6):651-8. PubMed ID: 17986200
[TBL] [Abstract][Full Text] [Related]
23. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Eikelboom JW; O'Donnell M; Yusuf S; Diaz R; Flaker G; Hart R; Hohnloser S; Joyner C; Lawrence J; Pais P; Pogue J; Synhorst D; Connolly SJ
Am Heart J; 2010 Mar; 159(3):348-353.e1. PubMed ID: 20211294
[TBL] [Abstract][Full Text] [Related]
24. How the direct oral anticoagulant apixaban affects thrombin generation parameters.
Tripodi A; Padovan L; Veena C; Scalambrino E; Testa S; Peyvandi F
Thromb Res; 2015 Jun; 135(6):1186-90. PubMed ID: 25895845
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor.
Paccaly A; Ozoux ML; Chu V; Simcox K; Marks V; Freyburger G; Sibille M; Shukla U
Thromb Haemost; 2005 Dec; 94(6):1156-63. PubMed ID: 16411387
[TBL] [Abstract][Full Text] [Related]
26. Coagulation and fibrinolytic markers in a two-month follow-up of coronary bypass surgery.
Parolari A; Colli S; Mussoni L; Eligini S; Naliato M; Wang X; Gandini S; Tremoli E; Biglioli P; Alamanni F
J Thorac Cardiovasc Surg; 2003 Feb; 125(2):336-43. PubMed ID: 12579103
[TBL] [Abstract][Full Text] [Related]
27. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.
Cohen M; Bhatt DL; Alexander JH; Montalescot G; Bode C; Henry T; Tamby JF; Saaiman J; Simek S; De Swart J;
Circulation; 2007 May; 115(20):2642-51. PubMed ID: 17502577
[TBL] [Abstract][Full Text] [Related]
28. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
[TBL] [Abstract][Full Text] [Related]
29. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
[TBL] [Abstract][Full Text] [Related]
30. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.
Luettgen JM; Knabb RM; He K; Pinto DJ; Rendina AR
J Enzyme Inhib Med Chem; 2011 Aug; 26(4):514-26. PubMed ID: 21171894
[TBL] [Abstract][Full Text] [Related]
31. Apixaban: an oral direct factor-xa inhibitor.
Jiménez D; Yusen RD; Ramacciotti E
Adv Ther; 2012 Mar; 29(3):187-201. PubMed ID: 22354465
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
Gheorghiade M; Thyssen A; Zolynas R; Nadar VK; Greenberg BH; Mehra M; Sun X; Tian H; Plotnikov AN; Burton P
J Heart Lung Transplant; 2011 Feb; 30(2):218-26. PubMed ID: 20947383
[TBL] [Abstract][Full Text] [Related]
33. Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans.
Hollenstein U; Homoncik M; Knöbl P; Pernerstorfer T; Graggaber J; Eichler HG; Handler S; Jilma B
Clin Pharmacol Ther; 2002 May; 71(5):368-74. PubMed ID: 12011822
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation.
Leitner JM; Jilma B; Mayr FB; Cardona F; Spiel AO; Firbas C; Rathgen K; Stähle H; Schühly U; Graefe-Mody EU
Clin Pharmacol Ther; 2007 Jun; 81(6):858-66. PubMed ID: 17410124
[TBL] [Abstract][Full Text] [Related]
35. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.
Yamahira N; Frost C; Fukase H; Yu Z; Wang J; Pursley J; LaCreta F; Hiraoka M
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):564-73. PubMed ID: 24725442
[TBL] [Abstract][Full Text] [Related]
36. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor.
Becker RC; Yang H; Barrett Y; Mohan P; Wang J; Wallentin L; Alexander JH
J Thromb Thrombolysis; 2011 Aug; 32(2):183-7. PubMed ID: 21516308
[TBL] [Abstract][Full Text] [Related]
37. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
Kruithof EK; Mestries JC; Gascon MP; Ythier A
Thromb Haemost; 1997 May; 77(5):905-10. PubMed ID: 9184401
[TBL] [Abstract][Full Text] [Related]
38. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
39. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
Schmitt C; Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
J Clin Pharmacol; 2012 Apr; 52(4):499-510. PubMed ID: 21566199
[TBL] [Abstract][Full Text] [Related]
40. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
